Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction based on clinical response.
The post Flexible Upadacitinib Dosing Effective in Moderate-to-Severe Atopic Dermatitis first appeared on Physician’s Weekly.
